Barclays
BIVV

Barclays’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Barclays’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-19,900
Closed -$1.07M – 7586
2017
Q4 		$1.07M Hold
19,900
– – ﹤0.01% 3056
2017
Q3 		$1.14M Sell
19,900
-7,250
-27% -$425K ﹤0.01% 2877
2017
Q2 		$1.63M Sell
27,150
-350
-1% -$19.9K ﹤0.01% 2427
2017
Q1 		$1.5M Buy
+27,500
New +$1.35M ﹤0.01% 2353

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Barclays's BIVV Position: Q1 2018 in Review

Barclays sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 45,770 shares — an estimated $2.47M sold.

Barclays first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $5.61M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Barclays reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 45,770 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $2.47M.
  • Barclays first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Barclays's Bioverativ Inc. Common Stock position peaked at $5.61M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.